Nexalin Technology Inc. (NXL)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET).
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and LOBO EV Technologies Ltd. (Nasdaq:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m.
Why Is Nexalin Technology (NXL) Stock Down 35% Today?
Nexalin Technology (NASDAQ: NXL ) stock is down on Friday after the medical device company priced a public offering of its shares. Nexalin Technology is selling 3 million shares of NXL stock for $1.75 each in this public offering.
Nexalin Technology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AH Amanda Hawley Atria Wealth Solutions Inc. | 10,347 | $17,486.43 | $4,449.21 | -$13,037.22 | -74.56% |
 Christopher C. Powers Farther Finance Advisors, LLC | 1,000 | $988 | $430 | -$558 | -56.48% |
Nexalin Technology Inc. (NXL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nexalin Technology Inc. ever had a stock split?
Nexalin Technology Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Mark White CEO | NASDAQ (CM) Exchange | 65345B201 CUSIP |
| US Country | 6 Employees | - Last Dividend | - Last Split | 16 Sep 2022 IPO Date |
Overview
Nexalin Technology, Inc. is a pioneering medical device company that specializes in creating advanced neurostimulation products aimed at improving mental health treatments. Operating both in the United States and China, the company has dedicated its expertise to addressing the challenging domain of mental health disorders including anxiety, insomnia, substance abuse issues, and cognitive disorders such as Alzheimer's disease and dementia. Leveraging non-invasive, drug-free therapies, Nexalin Technology stands at the forefront of revolutionizing mental health treatment by focusing on innovative, frequency-based waveform technology that stimulates the brain's mid-structures to counter various mental health conditions.
Products and Services
- Nexalin Device
- Generation 2 and Generation 3 Devices
A non-invasive, drug-free therapy device designed by Nexalin Technology, specifically targeting the treatment of anxiety and insomnia. The device operates on a patented frequency-based waveform that interacts with the mid-brain structures, eliciting a positive response crucial for overcoming these common mental health challenges.
As part of its continuous innovation, Nexalin Technology is in the process of designing and developing advanced versions of its original device, known as Generation 2 and Generation 3. These new iterations are currently undergoing clinical trials to expand their treatment capabilities to substance abuse related to opiates, cocaine, and alcohol. Additionally, these devices are being tested for their effectiveness in treating Alzheimer's disease and dementia, potentially offering a groundbreaking approach to managing these debilitating cognitive disorders.
